<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416649</url>
  </required_header>
  <id_info>
    <org_study_id>10-051-A</org_study_id>
    <nct_id>NCT01416649</nct_id>
  </id_info>
  <brief_title>Impact of Exenatide on Sleep Duration</brief_title>
  <official_title>Impact of Exenatide on Sleep Duration and Quality in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effect of exenatide, a FDA approved medication for the treatment
      of type 2 diabetes on sleep duration and quality. Individuals with type 2 diabetes will be
      studied before and during treatment with Exenatide.

      Enrolled individuals will be asked to come to the University of Chicago for 3-4 outpatient
      visits over the course of 3-4 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep duration and sleep efficiency</measure>
    <time_frame>at the end of 3 months of treatment with the medication</time_frame>
    <description>Sleep duration and efficiency will be measured using an activity monitor worn on the wrist.</description>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.</description>
    <other_name>The brand name of exenatide is Byetta.</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Convenience Sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients taking diabetes medications other then insulin will be included, but changes to
        their medications may be made as deemed necessary by their physician. Patients on stable
        medications for chronic and co-morbid conditions (high blood pressure, high cholesterol,
        etc) will be eligible

        Exclusion Criteria:

        Patients with moderate or severe kidney disease and history of pancreatitis or patients on
        insulin will be excluded, as Exenatide use is contraindicated or risky in these conditions.

        Patients with unstable cardiac, neurological or psychiatric disease and women who are
        pregnant or trying to get pregnant will be excluded. Patients who have severe COPD, severe
        neuropathy or chronic pain, which could impair sleep, will be excluded. Shift workers will
        be also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvana Pannain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annette Miller, MSN</last_name>
    <phone>773-834-8871</phone>
    <email>amiller@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Miller, MSN</last_name>
      <phone>773-834-8871</phone>
      <email>amiller@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Silvana Pannain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

